|
| |
|
| |
|
-- back to lectures --
|
| |
| Course Title: |
|
Aromatase Inhibitors as Initial Adjuvant Treatment for Postmenopausal Women with Breast Cancer: Long-Term Analyses of The ATAC and BIG 1-98 Trials |
|
|
|
| |
| |
Credit Hours: |
0.5 |
| Valid Until: |
1/19/2011 |
|
| |
Lecturer: |
Henning T. Mouridsen, MD, PhD |
|
Date Released: |
1/25/2009 |
|
| |
Affiliation: |
Department of Oncology
Rigshospitalet, Copenhagen
University Hospital, Copenhagen, Denmark |
| |
|
| |
View the Post-Test
|
| |
|
| |
| |
Lecture Overview: |
| |
| |
Hormonal therapy is the first line of treatment for hormone receptor (HR)-positive breast cancer, which accounts for approximately two thirds of all breast cancers. The HR-positive breast cancers are characterized by dependence on estrogen for their growth. As a result, therapeutic strategies have been developed to inhibit hormone-mediated tumor growth. For over 25 years, the selective estrogen receptor modulator tamoxifen has been considered the gold standard in the hormonal treatment therapy of breast cancer. More recently, however, third-generation aromatase inhibitors/inactivators (AIs), potent agents that suppress estrogen production, are being integrated into adjuvant treatment regimens. Questions remain regarding the optimal strategy for utilizing AIs in the adjuvant setting, and clinical trials have investigated their timing and duration of use, as well as further characterizing their side-effect profiles and long-term impact on quality of life.
This CME activity will provide a comprehensive review of the latest advances in the use of hormonal therapies for the treatment of estrogen sensitive breast cancer, and discuss clinical challenges and applications. |
| |
|
| |
| |
Target Audience: |
| |
| |
This activity is intended for oncologists and other healthcare professionals who treat patients with breast cancer. |
| |
|
| |
| |
Objectives: |
| |
| |
Following this program, participants will be able to demonstrate the following improvements:- Review the objectives and patient populations in the ATAC and BIG 1-98 trials
- Explain early benefits and toxicities demonstrated for upfront aromatase inhibitors as adjuvant therapy
- Interpret benefits shown in long-term analyses from ATAC and BIG 1-98 trials
- Discuss recent BIG 1-98 data on sequencing of agents in adjuvant therapy
|
| |
|
| |
| |
Lecturer Disclosure Statement: |
| |
| |
It is the policy of Medical Education Conferences, Inc. (MEC) and Total CME to ensure balance, independence, objectivity, and scientific rigor in all CME activities. All faculty are asked to disclose any financial relations with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity.
The following information was provided by each speaker:
Henning Mouridsen, MD, PhD
Novartis: Speaker/Advisory Boards |
| |
|
| |
| |
Accreditation Statement: |
| |
| |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Conferences, Inc. and Total CME, Inc. Medical Education Conferences, Inc (MEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Medical Education Conferences, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™ towards the AMA Physician Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity. |
| |
|
|
|
|
|
